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Abstract 
 
The first prospective trial of Eculizumab in pediatric aHUS is reported in this issue 
of Kidney International by Greenbaum et al. As in the adult trials of aHUS, 
Eculizumab appears effective and no serious safety signals were reported. There is 
the first suggestion of a dichotomy in response to treatment with a trend towards 
poorer outcome in those without complement abnormalities. This group however had 
worse renal function at presentation and it remains to be seen whether this 
represents true non-response or merely late presentation.  
 
 
  
The discovery of the role of the alternative pathway of complement in the 
pathogenesis of atypical haemolytic uraemic syndrome (aHUS) has led to a 
revolution in the treatment of the disease. 
Most individuals with aHUS have a latent genetic predisposition in the 
complement system (CFH, CFI, CD46, C3, CFB mutations) 1. Following a triggering 
stimuli, such as infection, disease manifests acutely with microangiopathic 
haemolytic anaemia (MAHA), thrombocytopenia and renal failure. Extrarenal 
manifestations are occasionally seen although it is unclear whether these are a 
direct consequence of complement activation; the thrombotic microangiopathy (TMA) 
process or the consequences of disease such as severe hypertension and uraemia.  
In 2013 Legendre et al 2 published the landmark study, demonstrating that 
complement blockade with eculizumab in adult patients with aHUS was effective. In 
this issue of Kidney International, Greenbaum et al 3  report the first prospective trial 
of Eculizumab in pediatric aHUS (<18yrs) with the efficacy mirroring that seen in the 
adult trial. As in the adult study this is a non randomised uncontrolled trial, however, 
this does not detract from its utility. The high morbidity and mortality rates described 
historically in aHUS 1 mean that the data is still informative. 
Overall the study population is representative of previously reported cohorts with 
~45% having a rare genetic variant in a complement gene or factor H autoantibody. 
The individual breakdown of mutation type revealed a slightly higher proportion of 
CD46 variants in relation to CFH variants than in the reported literature1. 
There were no reported episodes of meningococcal sepsis in the trial. In clinical 
practice, in both PNH and aHUS, meningococcal sepsis has been reported, 
prompting many centres to recommend long term antibiotic prophylaxis in addition to 
vaccination. 
Although only 64% of patients reached the primary end point of complete TMA 
response (platelet and LDH normalisation with a >25% plasma creatinine reduction) 
late presenting individuals with irretrievable renal impairment who have a complete 
resolution of the MAHA and thrombocytopenia cannot reach this end point. In 
keeping with this, the group that did not reach the primary end-point had worse renal 
function at presentation compared to those who did respond 3. 
Nevertheless it is intriguing to note that in those with a rare genetic variant in the 
complement system or an autoantibody to factor H, all had an improvement in eGFR 
≥15ml/min/1.73m2 however 27% of individuals without an identified complement 
abnormality failed to show an improvement in eGFR. This raises the possibility of a 
subgroup of non-complement mediated aHUS which do not respond to eculizumab. 
With the increased scrutiny of wider clinical practice such a group may reveal itself. It 
will be important to differentiate between non-responders and late presenters. 
It is interesting that in this cohort there was one individual who was subsequently 
demonstrated to have mutations in DGKE. The exact mechanism of action of these 
mutations are unclear and no definitive link to the complement system has yet to be 
elucidated. In the initial report by Lemaire et al  4 individuals had recurrent aHUS 
whilst on treatment with eculizumab. In this study the individual with the DGKE 
mutations achieved complete TMA response. It is too early to be clear as to the utility 
of complement blockade in this subgroup as it appears these individuals have a 
spontaneously remitting/relapsing disease which progresses over many years to 
ESRF. 
This work by Greenbaum et al 3 completes the first stage of the journey from the 
initial description of mutations in CFH to the successful use of the complement 
inhibitor eculizumab in both adults and children. 
Many questions still remain to be answered. First amongst them is the optimum 
duration of treatment. There is currently no evidence to justify life long therapy. In this 
study 2 individuals withdrew from eculizumab treatment without documented relapse 
of symptoms 5,6 .Unsurprisingly in a few individuals with underlying complement 
abnormalities there has been evidence of disease recurrence although eculizumab 
re-introduction led to normalisation of renal function 5,6. Clinical trials comparing 
continuous vs. disease-driven intermittent treatment are required to determine the 
best regime.  These should be stratified according by mutation type as certain 
mutations (e.g. CD46) have a good prognosis even without treatment 7. 
Additionally, the trials of eculizumab have so far excluded potential secondary 
causes of aHUS, such as bone marrow transplantation (BMT) 8 associated TMA. As 
alluded to above, even in individuals with complement mutations, disease requires a 
trigger to manifest. As such it can be unclear whether these triggers have a direct 
effect or only have a role in the context of an underlying complement mutation.  
Genetic characterisation and clinical trials of eculizumab in these secondary cohorts 
will be required prior to recommending its use in these cases. 
In summary, eculizumab appears effective in treating both adult and pediatric 
aHUS. It remains to define the optimal treatment regimen to minimise the infectious 
complications of terminal pathway complement blockade. Such a strategy will also 
minimise the financial impact of this highly expensive monoclonal antibody on those 
few countries that can afford eculizumab. 
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